Browsing Tag
Multiple myeloma
50 posts
Legend Biotech soars 42% on ASCO data as CAR-T momentum extends from blood cancers toward solid tumors
Legend Biotech soared 42% on ASCO data: a survival readout for myeloma CAR-T CARVYKTI plus early solid-tumor results for LB2102. Big ramp, but still loss-making.
Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial
Bristol Myers Squibb's mezigdomide doubled myeloma progression-free survival to 18 months and cut progression or death risk 52% in Phase 3, key to its patent-cliff plan.
Can parallel CAR-T targeting finally solve relapse in multiple myeloma
Can dual-targeting CAR-T solve relapse in multiple myeloma? Explore how Tempest Therapeutics, Inc. is positioning TPST-2003 for next-gen impact.
Is TPST-2003’s early efficacy enough to disrupt the current CAR-T landscape in multiple myeloma
Can TPST-2003 disrupt CAR-T therapy in multiple myeloma? Explore what Tempest Therapeutics, Inc.’s strategy means for investors and the industry.
Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership
Biogen pays $100M upfront for felzartamab's China rights from TJ Biopharma, completing global ownership of the CD38 antibody with up to $850M at stake. Read the full analysis.
Why a tiny cancer biotech suddenly looks worth more than $2bn to Eli Lilly
Eli Lilly is reportedly nearing a $2 billion-plus Kelonia deal. Read what it could mean for Lilly’s cancer pipeline, CAR-T economics, and LLY stock.
Gilead Sciences to double down on CAR T with $7.8bn Arcellx acquisition
Find out how Gilead Sciences’ $7.8 billion Arcellx acquisition reshapes the future of anito-cel and the competitive landscape in multiple myeloma.
What continuous drug exposure could mean for immunomodulatory therapy in multiple myeloma
Can continuous lenalidomide exposure reshape immunomodulatory therapy economics? Explore the strategic stakes for Starton Therapeutics Inc.
CARsgen showcases early clinical results for CT0596 allogeneic BCMA CAR-T cell therapy in multiple myeloma
CARsgen unveils early CT0596 CAR-T trial results at ASH 2025, showing deep responses and strong tolerability in multiple myeloma. See what’s next for the therapy.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.